NASDAQ:CELC

Celcuity (CELC) Stock Forecast, Price & News

$11.11

+0.17 (+1.55%)

(As of 06/9/2023 ET)

Compare

Today's Range: $10.89
▼
$11.42
50-Day Range: $9.39
▼
$11.31
52-Week Range: $7.42
▼
$14.40

Volume: 50,618 shs
Average Volume: 44,868 shs
Market Capitalization: $240.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Celcuity MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
12.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$6,422 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.69) to ($2.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.08 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Celcuity.

0.0

Short Interest

Percentage of Shares Shorted
12.75% of the float of Celcuity has been sold short.
Short Interest Ratio / Days to Cover
Celcuity has a short interest ratio ("days to cover") of 17.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Celcuity has recently increased by 171.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Celcuity does not currently pay a dividend.
Dividend Growth
Celcuity does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CELC.

2.7

News and Social Media Coverage

News Sentiment
Celcuity has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Celcuity this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,422.00 in company stock.
Percentage Held by Insiders
24.29% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 31.05% of the stock of Celcuity is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Celcuity are expected to grow in the coming year, from ($2.69) to ($2.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Celcuity is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Celcuity is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Celcuity has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Celcuity (NASDAQ:CELC) Stock

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

CELC Stock News Headlines

May 24, 2023 | finance.yahoo.com

Insiders of Celcuity Getting Good Value On Their US$1.6m Investment

May 16, 2023 | msn.com

Needham Reiterates Celcuity (CELC) Buy Recommendation

June 10, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 16, 2023 | finance.yahoo.com

Q1 2023 Celcuity Inc Earnings Call

May 15, 2023 | finance.yahoo.com

Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

May 15, 2023 | markets.businessinsider.com

Craig-Hallum Keeps Their Buy Rating on Celcuity (CELC)

May 14, 2023 | americanbankingnews.com

Celcuity (CELC) Scheduled to Post Earnings on Monday

May 13, 2023 | marketwatch.com

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naive Patients at the 2023 ESMO Breast Cancer Annual Congress

June 10, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

May 12, 2023 | msn.com

A Preview Of Celcuity's Earnings

May 12, 2023 | msn.com

Celcuity gedatolisib combo shows promise in phase 1b trial in breast cancer patients

May 8, 2023 | finance.yahoo.com

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

May 8, 2023 | finance.yahoo.com

Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress

April 22, 2023 | americanbankingnews.com

Analyzing Celcuity (NASDAQ:CELC) & Aclarion (NASDAQ:ACON)

April 18, 2023 | finance.yahoo.com

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

April 12, 2023 | finanznachrichten.de

Celcuity Inc.: Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023 | finance.yahoo.com

Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference

March 27, 2023 | insidermonkey.com

Celcuity Inc. (NASDAQ:CELC) Q4 2022 Earnings Call Transcript

March 26, 2023 | markets.businessinsider.com

Craig-Hallum Remains a Buy on Celcuity (CELC)

March 26, 2023 | markets.businessinsider.com

Craig-Hallum Initiates a Buy Rating on Celcuity (CELC)

March 24, 2023 | finance.yahoo.com

Q4 2022 Celcuity Inc Earnings Call

March 23, 2023 | finance.yahoo.com

Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 16, 2023 | finance.yahoo.com

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call

March 15, 2023 | finance.yahoo.com

Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

March 1, 2023 | finance.yahoo.com

Celcuity to Participate in Cowen's 43rd Annual Health Care Conference

February 17, 2023 | finance.yahoo.com

While institutions own 25% of Celcuity Inc. (NASDAQ:CELC), individual investors are its largest shareholders with 58% ownership

February 16, 2023 | finance.yahoo.com

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

See More Headlines

CELC Price History

30 days | 90 days | 365 days | Advanced Chart

CELC Company Calendar

Last Earnings: 3/23/2023
Today: 6/10/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CELC
CUSIP: N/A
CIK: 1603454
Web: www.celcuity.com
Phone: (763) 392-0767
Fax: N/A
Employees: 39
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -50.18%
Return on Assets: -37.12%

Debt

Debt-to-Equity Ratio: 0.29
Current Ratio: 28.26
Quick Ratio: 28.26

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.17 per share
Price / Book: 1.80

Miscellaneous

Outstanding Shares: 21,690,000
Free Float: 16,421,000
Market Cap: $240.98 million
Optionable: Not Optionable
Beta: 0.60

Key Executives

Brian F. Sullivan
Chairman & Chief Executive Officer

Vicky Hahne
Chief Financial Officer

Lance G. Laing
Secretary, Director & Chief Science Officer

Arthur P. DeCillis
Chief Medical Officer

Sheri Smith
Head-Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CELC Stock - Frequently Asked Questions

How have CELC shares performed in 2023?: Celcuity's stock was trading at $14.01 at the start of the year. Since then, CELC stock has decreased by 20.7% and is now trading at $11.11.
View the best growth stocks for 2023 here.
When is Celcuity's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our CELC earnings forecast.
How were Celcuity's earnings last quarter?: Celcuity Inc. (NASDAQ:CELC) posted its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.15.
What other stocks do shareholders of Celcuity own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID).
When did Celcuity IPO?: (CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is Celcuity's stock symbol?: Celcuity trades on the NASDAQ under the ticker symbol "CELC."
Who are Celcuity's major shareholders?: Celcuity's stock is owned by a variety of retail and institutional investors. Top institutional investors include Commodore Capital LP (6.41%), Geode Capital Management LLC (0.61%), BlackRock Inc. (0.60%), Jacob Asset Management of New York LLC (0.31%), Citigroup Inc. (0.15%) and Renaissance Technologies LLC (0.13%). Insiders that own company stock include Brian F Sullivan, Richard E Buller and Richard Nigon.
View institutional ownership trends.
How do I buy shares of Celcuity?: Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Celcuity's stock price today?: One share of CELC stock can currently be purchased for approximately $11.11.
How much money does Celcuity make?: Celcuity (NASDAQ:CELC) has a market capitalization of $240.98 million. The company earns $-40,370,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis.
How can I contact Celcuity?: Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The official website for the company is www.celcuity.com. The company can be reached via phone at (763) 392-0767.

This page (NASDAQ:CELC) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial